by April Breyer Menon | Aug 7, 2023
At the beginning of July, seven additional Humira® (adalimumab) biosimilars, including one interchangeable, joined Amjevita™ (adalimumab-atto) in the US marketplace. Abrilada™ (adalimumab-afzb) is the only FDA-approved adalimumab biosimilar that has not...
by April Breyer Menon | Jul 31, 2023
As of July 24, 2023, the United States Patent and Trademark Office (USPTO) revised the interim Director Review process and replaced the Precedential Opinion Panel (POP) with the Appeals Review Panel process, which will review decisions in ex parte, re-examination, and...
by April Breyer Menon | Jul 15, 2023
Download PDF Download...
by April Breyer Menon | Jun 30, 2023
On June 22, 2023, Senators Thom Tillis (R-N.C.) and Chris Coons (D-Del.) announced the reintroduction of legislation to reform the patent eligibility requirements under 35 U.S.C. § 101. The “Patent Eligibility and Restoration Act of 2023,” similar to the...
by April Breyer Menon | Jun 13, 2023
Download PDF Download...